Core Insights - CorMedix Therapeutics will present a corporate overview at the 44th annual J.P. Morgan Healthcare Conference on January 12, 2026, at 4:30pm PST [1][2] Company Overview - CorMedix Therapeutics is focused on developing and commercializing therapeutic products for life-threatening diseases and conditions [2] - The company is commercializing DefenCath® for the prevention of catheter-related bloodstream infections in adult patients undergoing hemodialysis via a central venous catheter [2] - Following the acquisition of Melinta Therapeutics LLC in August 2025, CorMedix is also commercializing a portfolio of anti-infective products, including MINOCIN®, REZZAYO®, VABOMERE®, ORBACTIV™, BAXDELA®, and KIMYRSA®, as well as TOPROL-XL® [2] Clinical Studies and Developments - CorMedix has ongoing clinical studies for DefenCath in Total Parenteral Nutrition (TPN) and Pediatric Hemodialysis populations [3] - The company intends to develop DefenCath as a catheter lock solution for use in other patient populations [3] - REZZAYO is currently approved for the treatment of candidemia and invasive candidiasis in adults, with an ongoing Phase III study for the prophylaxis of invasive fungal disease (IFD) in adult patients undergoing allogeneic bone marrow transplantation (BMT) [3] - Topline results of the Phase III study for REZZAYO are expected in Q2 2026 [3]

Core Insights - CorMedix Inc. will report its financial results for Q3 2025 on November 12, 2025, before market opens and will host a conference call at 8:30 AM ET [1] - The company focuses on developing therapeutic products for life-threatening diseases, including its commercialized product DefenCath for preventing catheter-related bloodstream infections [3] Company Overview - CorMedix is a biopharmaceutical company that has commercialized DefenCath (taurolidine and heparin) for adult patients undergoing hemodialysis [3] - Following the acquisition of Melinta Therapeutics in August 2025, CorMedix is also marketing a range of anti-infective products, including MINOCIN®, REZZAYO®, VABOMERE®, ORBACTIV™, BAXDELA®, and KIMYRSA® [3] Clinical Studies and Developments - Ongoing clinical studies for DefenCath include applications in Total Parenteral Nutrition and pediatric populations, with plans to develop it as a catheter lock solution for other patient groups [4] - REZZAYO is approved for treating candidemia and invasive candidiasis in adults, with a Phase III study for prophylaxis of invasive fungal disease (IFD) in adult patients undergoing allogeneic bone marrow transplantation, with topline results expected in Q2 2026 [4]